Company: ARVN
Filing Date: 2025-02-11
Form Type: 10-K
Source: 0001655759-25-000016
Chunk: 229

Company: ARVINAS, INC.
Filing Date: 2025-02-11
Form: 10-K
Item: Item 1A
Chunk 229
---
 our product candidates, if approved for commercial sale, will depend on a number of factors, including, but not limited to: 

•the efficacy and potential advantages as compared to alternative treatments; 

•the prevalence and severity of any side effects of our product candidates, in particular as compared to alternative treatments; 

•our ability to offer our products for sale at competitive prices; 

•the convenience and ease of administration compared to alternative treatments; 

•the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; 

•the strength of marketing, sales and distribution support; 

•the availability of third-party coverage and adequate reimbursement; 

•the timing of any marketing approval in relation to other product approvals; 

•support from patient advocacy groups; and 

•any restrictions on the use of our products together with other medications. 

If we are unable to establish sales and marketing capabilities, we may not be successful in commercializing our product candidates if and when they are approved. 

Though we are working to build, we do not currently have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of biopharmaceutical products. To achieve commercial success for any product for which we obtain marketing approval, we will need to establish sales, marketing and distribution capabilities, either ourselves or through collaboration or other arrangements with third parties. 

We currently expect that we would continue to build our own focused, specialized sales, marketing and market access organization to support the commercialization of our product candidates in the United States for which we receive marketing approval and that can be commercialized with such capabilities. There are risks involved with establishing our own sales and marketing capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. These efforts may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. 

Factors that may inhibit our efforts to commercialize our products on our own include: 

•our inability to recruit, train and retain adequate numbers of effective, knowledgeable and experienced sales and marketing personnel;

•the inability of such sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products;

•the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage